share_log

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

更正:在 2023 年 1 月 19 日,Biora 治療學收到納斯達克的一封信通知該公司。該有限公司 's 先前宣布的投標價格缺陷已經治愈和 Co.符合所有適用的持續上市標準
Benzinga Real-time News ·  2023/01/23 08:57

CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards

更正:在 2023 年 1 月 19 日,Biora 治療學收到納斯達克的一封信通知該公司。該有限公司 's 先前宣布的投標價格缺陷已經治愈和 Co.符合所有適用的持續上市標準

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論